Different types of vasculitis have been reported in association with hepatitis C virus (HCV) infection, i.e. type II mixed cryoglobulinemia and polyarteritis nodosa (PAN). Therapeutic approach of such severely symptomatic patients include interferon-alpha (IFN) plus plasma exchange (PE). There are no data on IFN pharmacokinetic changes related to PE. Patients and Methods: We studied 7 HCV-infected patients (mean age: 57 years) presenting with symptomatic type II mixed cryoglobulinemia (n = 5) or biopsy-proven PAN (n = 2). All patients underwent subcutaneous IFN therapy with concomitant PE. Serum IFN concentration was measured in serial samples on days with and without PE. Results: Without PE, IFN Cmax (range: 100–750 IU/ml) was obtained 3–6 h after subcutaneous injection, followed by a 3- to 9-hour plateau. IFN concentration declined subsequently reaching a residual concentration 24 h after injection, ranging from 20 to 40 IU/ml. PE performed 6 h after IFN administration resulted in increased IFN clearance in that the concentration-time IFN-α area under the curve decreased from 3,005 IU·h/ml (1,563–4,614) on days without PE to 2,142 IU·h/ml (973–4,123) on day with PE. Conclusions: In patients with HCV-associated vasculitis, PE increase IFN clearance. Combined IFN-α and PE therapy schedule have to be further studied to optimize its biological activity.

Keywords:
Hepatitis C virus, Mixed cryoglobulinemia, Vasculitis, Polyarteritis nodosa, Interferon-alpha, Pharmacokinetics
1.
Cacoub P, Fabiani FL, Musset L, Perrin M, Frangeul L, Leger JM, Huraux JM, Piette JC, Godeau P: Mixed cryoglobulinemia and hepatitis C virus. Am J Med 1994;96:124–132.
2.
Cacoub P, Poynard T, Ghillani P, Charlotte F, Olivi M, Piette JC, Opolon P: Extrahepatic manifestations in patients with chronic hepatitis C. Arthritis Rheum 1999;42:2204–2212.
3.
Cacoub P, Maisonobe T, Thibault V, Gatel A, Servan J, Musset L, Piette JC: Systemic vasculitis in patients with hepatitis C. J Rheumatol 2001;28:109–118.
4.
Lightfoot RW Jr, Michel BA, Bloch DA, Hunder GG, Zvaifler NJ, McShane DJ, Arend WP, Calabrese LH, Leavitt RY, Lie JT, et al: The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. Arthritis Rheum 1990;33:1088–1093.
5.
Lebon P, Badoual P, Ponsot G, Gouttières F, Hémeury-Cukier F, Aicardi J: Intrathecal synthesis of interferon alpha in infants with progressive familial encephalopathy. J Neurol Sci 1988;84:201–208.
6.
Wills RJ: Clinical pharmacokinetics of interferons. Clin Pharmacokinet 1990;19:390–399.
7.
Rostaing L, Chatelup E, Payen JL, Izopet J, Thalamas C, Ton-That H, Pascal JP, Durand D, Canal P: Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: Clinical implications. J Am Soc Nephrol 1998;9:2344–2348.
8.
Uchihara M, Izumi N, Sakai Y, Yauchi T, Miyake S, Sakai T, Akiba T, Marumo F, Sato C: Interferon therapy for chronic hepatitis C in hemodialysis patients: Increased serum levels of interferon. Nephron 1998;80:51–56.
9.
Chatelut E, Rostaing L, Gregoire N, Payen JL, Pujol A, Izopet J, Houin G, Canal P: A pharmacokinetic model for alpha interferon administered subcutaneously. Br J Clin Pharmacol 1999;47:365–371.
10.
Fauvelle F, Petitjean O, Tod M, Guillevin L: Clinical pharmacokinetics during plasma exchange. Therapie 2000;55:269–275.
11.
Manzin A, Candela M, Solforosi L, Armando G, Clementi M: Dynamics of hepatitis C viremia after plasma exchange. J Hepatol 1999;31:389–393.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.